https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-11-april-2027-week-16-ca3f873b714c8310PharmaRadar360en2026-09-29T11:00:48.000ZWeekly all-cause mortality surveillance: week ending 11 April 2027 (week 16)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-4-april-2027-week-15-ce1c58e5f998d36fPharmaRadar360en2026-09-29T10:59:49.000ZWeekly all-cause mortality surveillance: week ending 4 April 2027 (week 15)https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-1b4c313e4093d4bbPharmaRadar360en2026-09-29T10:59:25.000ZAdult social care client level data, England: quarterly updatehttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-march-2026-f6bcfb810bad2e74PharmaRadar360en2026-09-29T10:59:08.000ZAdult social care client level data, England: quarterly update to March 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-march-2027-week-14-fce9bba549e24234PharmaRadar360en2026-09-29T10:59:02.000ZWeekly all-cause mortality surveillance: week ending 28 March 2027 (week 14)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-march-2027-week-13-3bc55aa6606b07f8PharmaRadar360en2026-09-29T10:57:32.000ZWeekly all-cause mortality surveillance: week ending 21 March 2027 (week 13)https://www.pharmaradar360.com/article/china-acetonitrile-market-tightens-as-glp-1-api-production-drives-demand-2be736315a8a8ce9PharmaRadar360en2026-09-29T10:57:32.000ZChina Acetonitrile Market Tightens as GLP-1 API Production Drives Demandhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-14-march-2027-week-12-59f14363f8f5e93bPharmaRadar360en2026-09-29T10:56:53.000ZWeekly all-cause mortality surveillance: week ending 14 March 2027 (week 12)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-7-march-2027-week-11-3ed26e34062d9b47PharmaRadar360en2026-09-29T10:56:06.000ZWeekly all-cause mortality surveillance: week ending 7 March 2027 (week 11)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-february-2027-week-10-b24ebd3685f4e740PharmaRadar360en2026-09-29T10:55:04.000ZWeekly all-cause mortality surveillance: week ending 28 February 2027 (week 10)https://www.pharmaradar360.com/article/la-aemps-informa-de-un-error-de-embalaje-en-un-lote-de-apositos-aquacel-foam-pro-1b33bfa56e7f6818PharmaRadar360en2026-09-29T10:49:55.000ZLa AEMPS informa de un error de embalaje en un lote de apósitos Aquacel Foam Prohttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-february-2027-week-9-3c8feae5609ae716PharmaRadar360en2026-09-29T10:46:41.000ZWeekly all-cause mortality surveillance: week ending 21 February 2027 (week 9)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-14-february-2027-week-8-b16d8a4c5c1a754dPharmaRadar360en2026-09-29T10:45:18.000ZWeekly all-cause mortality surveillance: week ending 14 February 2027 (week 8)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-7-february-2027-week-7-9768c2ec72a62b4cPharmaRadar360en2026-09-29T10:44:42.000ZWeekly all-cause mortality surveillance: week ending 7 February 2027 (week 7)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-31-january-2027-week-6-4471b50b08dff893PharmaRadar360en2026-09-29T10:44:10.000ZWeekly all-cause mortality surveillance: week ending 31 January 2027 (week 6)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-24-january-2027-week-5-4c66d74393bb12ecPharmaRadar360en2026-09-29T10:43:30.000ZWeekly all-cause mortality surveillance: week ending 24 January 2027 (week 5)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-17-january-2027-week-4-fc1df6de70aa1ff9PharmaRadar360en2026-09-29T10:42:47.000ZWeekly all-cause mortality surveillance: week ending 17 January 2027 (week 4)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-10-january-2027-week-3-2d3c9dafa72e3b82PharmaRadar360en2026-09-29T10:42:05.000ZWeekly all-cause mortality surveillance: week ending 10 January 2027 (week 3)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-3-january-2027-week-2-4ff9b88d82c308adPharmaRadar360en2026-09-29T10:41:19.000ZWeekly all-cause mortality surveillance: week ending 3 January 2027 (week 2)https://www.pharmaradar360.com/article/c8b49044706e84fePharmaRadar360en2026-09-29T10:38:09.000ZΕνημέρωση για την υποβολή των αιτημάτων τιμολόγησηςhttps://www.pharmaradar360.com/article/us-waives-100-pc-tariff-on-select-indian-speciality-drugs-what-it-means-for-phar-a59935bbf63a46d2PharmaRadar360en2026-09-29T10:30:00.000ZUS waives 100 pc tariff on select Indian speciality drugs: What it means for pharma industryhttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-reclaims-belvarafenib-rights-after-10-years-as-genentech-te-50db590e1c7b168fPharmaRadar360en2026-09-29T10:25:00.000ZHanmi Pharmaceutical Reclaims Belvarafenib Rights After 10 Years as Genentech Terminates Agreementhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-initiates-phase-ib-clinical-trial-of-jmt206-injection-in-chi-916af4573c06f57aPharmaRadar360en2026-09-29T10:21:26.000ZCSPC Pharmaceutical Initiates Phase IB Clinical Trial Of JMT206 Injection In Chinahttps://www.pharmaradar360.com/article/fonds-de-solidarite-ftq-snares-another-foreign-fund-to-back-local-biotech-startu-f3526de9592a39a6PharmaRadar360en2026-09-29T10:00:00.000ZFonds de solidarité FTQ snares another foreign fund to back local biotech startupshttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-22-report-data-to-week-21-dat-e26450353adf8cc9PharmaRadar360en2026-09-29T09:58:09.000ZNational flu and COVID-19 surveillance report, week 22 report: data to week 21 (data up to 23 May 2027)https://www.pharmaradar360.com/article/india-s-sun-pharma-plans-1-billion-local-debt-sale-for-loan-takeout-sources-say-89625efa6dacb9dcPharmaRadar360en2026-09-29T09:57:51.000ZIndia's Sun Pharma plans $1 billion local debt sale for loan takeout, sources sayhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-21-report-data-to-week-20-dat-eb9151086d6e9097PharmaRadar360en2026-09-29T09:56:28.000ZNational flu and COVID-19 surveillance report, week 21 report: data to week 20 (data up to 16 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-20-report-data-to-week-19-dat-e6e641100e95a23bPharmaRadar360en2026-09-29T09:55:55.000ZNational flu and COVID-19 surveillance report, week 20 report: data to week 19 (data up to 9 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-19-report-data-to-week-18-dat-a1383c1237b314a4PharmaRadar360en2026-09-29T09:55:37.000ZNational flu and COVID-19 surveillance report, week 19 report: data to week 18 (data up to 2 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-18-report-data-to-week-17-dat-f7b834d10f61e6d1PharmaRadar360en2026-09-29T09:55:25.000ZNational flu and COVID-19 surveillance report, week 18 report: data to week 17 (data up to 25 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-17-report-data-to-week-16-dat-42aecb93111f49c0PharmaRadar360en2026-09-29T09:55:06.000ZNational flu and COVID-19 surveillance report, week 17 report: data to week 16 (data up to 18 April 2027)https://www.pharmaradar360.com/article/teva-pharmaceutical-3-numbers-that-explain-this-generic-drug-turnaround-5f1cb0bbe32b13ddPharmaRadar360en2026-09-29T09:55:00.000ZTeva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaroundhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-16-report-data-to-week-15-dat-373827dc7348e461PharmaRadar360en2026-09-29T09:54:54.000ZNational flu and COVID-19 surveillance report, week 16 report: data to week 15 (data up to 11 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-11-report-data-to-week-10-dat-65ae1db376478d6cPharmaRadar360en2026-09-29T09:54:28.000ZNational flu and COVID-19 surveillance report, week 11 report: data to week 10 (data up to 7 March 2027)https://www.pharmaradar360.com/article/hanmi-pharmaceutical-will-receive-back-the-rights-of-belbarafenib-hm95573-a-targ-cf56a8c6030d0d97PharmaRadar360en2026-09-29T09:54:19.000ZHanmi Pharmaceutical will receive back the rights of "Belbarafenib (HM95573), a target anticancer dr..https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-15-report-data-to-week-14-dat-cb071690108f0c13PharmaRadar360en2026-09-29T09:53:24.000ZNational flu and COVID-19 surveillance report, week 15 report: data to week 14 (data up to 4 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-14-report-data-to-week-13-dat-f34f7e46e0cbc218PharmaRadar360en2026-09-29T09:53:04.000ZNational flu and COVID-19 surveillance report, week 14 report: data to week 13 (data up to 28 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-13-report-data-to-week-12-dat-2248d925c1565b0bPharmaRadar360en2026-09-29T09:52:35.000ZNational flu and COVID-19 surveillance report, week 13 report: data to week 12 (data up to 21 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-12-report-data-to-week-11-dat-d006ba9728d2f42bPharmaRadar360en2026-09-29T09:52:15.000ZNational flu and COVID-19 surveillance report, week 12 report: data to week 11 (data up to 14 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-11-report-data-to-week-10-dat-3fe56562c6576c96PharmaRadar360en2026-09-29T09:50:56.000ZNational flu and COVID-19 surveillance report, week 11 report: data to week 10 (data up to 7 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-10-report-data-to-week-9-data-da8467c5e0181f25PharmaRadar360en2026-09-29T09:49:26.000ZNational flu and COVID-19 surveillance report, week 10 report: data to week 9 (data up to 28 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-9-report-data-to-week-8-data-9c8304d98790e067PharmaRadar360en2026-09-29T09:49:06.000ZNational flu and COVID-19 surveillance report, week 9 report: data to week 8 (data up to 21 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-8-report-data-to-week-7-data-3361a06bc06c6f4bPharmaRadar360en2026-09-29T09:48:34.000ZNational flu and COVID-19 surveillance report, week 8 report: data to week 7 (data up to 14 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-7-report-data-to-week-6-data-440549a3da1d18e2PharmaRadar360en2026-09-29T09:48:22.000ZNational flu and COVID-19 surveillance report, week 7 report: data to week 6 (data up to 7 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-6-report-data-to-week-5-data-2670f011693f7bf0PharmaRadar360en2026-09-29T09:48:09.000ZNational flu and COVID-19 surveillance report, week 6 report: data to week 5 (data up to 31 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-5-report-data-to-week-4-data-a451d64aae8e2df2PharmaRadar360en2026-09-29T09:47:53.000ZNational flu and COVID-19 surveillance report, week 5 report: data to week 4 (data up to 24 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-4-report-data-to-week-3-data-f473d78c142df7fePharmaRadar360en2026-09-29T09:47:27.000ZNational flu and COVID-19 surveillance report, week 4 report: data to week 3 (data up to 17 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-3-report-data-to-week-2-data-dd4d02f23e4aa08fPharmaRadar360en2026-09-29T09:47:12.000ZNational flu and COVID-19 surveillance report, week 3 report: data to week 2 (data up to 10 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-2-report-data-to-week-1-data-72725bd97f2ed752PharmaRadar360en2026-09-29T09:46:53.000ZNational flu and COVID-19 surveillance report, week 2 report: data to week 1 (data up to 3 January 2027)https://www.pharmaradar360.com/article/teva-pharmaceutical-3-numbers-that-explain-this-generic-drug-turnaround-105d8470c4e8ab35PharmaRadar360en2026-09-29T09:42:07.000ZTeva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaroundhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-9-report-data-to-week-8-data-up-to-440890632af845c7PharmaRadar360en2026-09-29T09:39:59.000ZNational Norovirus and Rotavirus Report, week 9 report: data to week 8 (data up to 21 February 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-8-report-data-to-week-7-data-up-to-40e654f04f9dd53ePharmaRadar360en2026-09-29T09:39:38.000ZNational Norovirus and Rotavirus Report, week 8 report: data to week 7 (data up to 14 February 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-7-report-data-to-week-6-data-up-to-c67d1789132305e1PharmaRadar360en2026-09-29T09:39:09.000ZNational Norovirus and Rotavirus Report, week 7 report: data to week 6 (data up to 7 February 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-6-report-data-to-week-5-data-up-to-cb295ce1da50e73dPharmaRadar360en2026-09-29T09:38:55.000ZNational Norovirus and Rotavirus Report, week 6 report: data to week 5 (data up to 31 January 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-5-report-data-to-week-4-data-up-to-2e74c55ab5f0ff0cPharmaRadar360en2026-09-29T09:38:39.000ZNational Norovirus and Rotavirus Report, week 5 report: data to week 4 (data up to 24 January 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-4-report-data-to-week-3-data-up-to-66b5e36a07bd61ecPharmaRadar360en2026-09-29T09:38:08.000ZNational Norovirus and Rotavirus Report, week 4 report: data to week 3 (data up to 17 January 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-3-report-data-to-week-2-data-up-to-181cb601dccffd9bPharmaRadar360en2026-09-29T09:37:45.000ZNational Norovirus and Rotavirus Report, week 3 report: data to week 2 (data up to 10 January 2027)https://www.pharmaradar360.com/article/astrazeneca-seeks-fda-nod-for-lung-cancer-combo-7838b39927a50718PharmaRadar360en2026-09-29T09:37:33.000ZAstraZeneca Seeks FDA Nod for Lung Cancer Combohttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-2-report-data-to-week-1-data-up-to-8b8ede5ebd065d46PharmaRadar360en2026-09-29T09:37:25.000ZNational Norovirus and Rotavirus Report, week 2 report: data to week 1 (data up to 3 January 2027)https://www.pharmaradar360.com/article/biotech-stocks-facing-fda-decision-in-october-2026-689260599cd2081dPharmaRadar360en2026-09-29T09:33:00.000ZBiotech Stocks Facing FDA Decision In October 2026https://www.pharmaradar360.com/article/milan-based-biotech-aptadir-therapeutics-raises-45m-seed-round-2f524a461e61779fPharmaRadar360en2026-09-29T09:24:22.000ZMilan-based biotech Aptadir Therapeutics raises $45M seed roundhttps://www.pharmaradar360.com/article/jw-pharmaceutical-buys-group-s-venture-capital-arm-for-30-7-billion-won-98488fc47817d212PharmaRadar360en2026-09-29T09:17:04.000ZJW Pharmaceutical Buys Group's Venture Capital Arm for 30.7 Billion Wonhttps://www.pharmaradar360.com/article/astrazeneca-merck-novo-deals-inject-fresh-global-momentum-into-chinese-biotech-fd6988446cf5bef2PharmaRadar360en2026-09-29T09:00:07.000ZAstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotechhttps://www.pharmaradar360.com/article/regulatory-round-up-29-september-2026-cbbe545bbdf4eba8PharmaRadar360en2026-09-29T08:52:42.000ZRegulatory round-up: 29 September 2026https://www.pharmaradar360.com/article/adult-social-care-activity-report-england-2025-to-2026-d04cfc1369caa66dPharmaRadar360en2026-09-29T08:33:53.000ZAdult social care activity report, England: 2025 to 2026https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-june-2026-1e59638994dbd075PharmaRadar360en2026-09-29T08:33:22.000ZAdult social care client level data, England: quarterly update to June 2026https://www.pharmaradar360.com/article/1-in-7-science-institute-dropouts-enter-medical-fields-7991e7177fffe10ePharmaRadar360en2026-09-29T08:32:53.000Z1 in 7 Science Institute Dropouts Enter Medical Fieldshttps://www.pharmaradar360.com/article/us-exempts-select-indian-speciality-drugs-from-100-tariff-as-wider-pharma-levy-k-eab32954db189a91PharmaRadar360en2026-09-29T08:24:00.000ZUS exempts select Indian speciality drugs from 100% tariff as wider pharma levy kicks inhttps://www.pharmaradar360.com/article/inxmed-raf-mek-spyk04-fe07167db3fcd48aPharmaRadar360en2026-09-29T08:00:00.000Z中外製薬とInxMed、RAF-MEK分子糊SPYK04に関する全世界におけるライセンス契約を締結https://www.pharmaradar360.com/article/chugai-and-inxmed-enter-into-a-worldwide-license-agreement-for-spyk04-a-raf-mek-cc0dcf063531e4f3PharmaRadar360en2026-09-29T08:00:00.000ZChugai and InxMed Enter into a Worldwide License Agreement for SPYK04, a RAF-MEK Molecular Gluehttps://www.pharmaradar360.com/article/south-korea-boosts-cmc-to-lift-drug-approvals-and-biopharma-competitiveness-chos-7cac7ad346d5f1acPharmaRadar360en2026-09-29T07:58:00.000ZSouth Korea boosts CMC to lift drug approvals and biopharma competitiveness - CHOSUNBIZhttps://www.pharmaradar360.com/article/results-are-due-monday-from-a-study-of-two-potential-treatments-for-an-age-relat-87cd3e491349b862PharmaRadar360en2026-09-29T07:31:02.000ZResults are due Monday from a study of two potential treatments for an age-related eye disease.https://www.pharmaradar360.com/article/building-more-sustainable-laboratories-with-my-green-lab-4509b122e94639cbPharmaRadar360en2026-09-29T07:00:00.000ZBuilding more sustainable laboratories with My Green Labhttps://www.pharmaradar360.com/article/arthex-biotech-announces-appointment-of-glenn-p-sblendorio-as-chairman-of-the-bo-7c8ca2bfb5283207PharmaRadar360en2026-09-29T07:00:00.000ZARTHEx Biotech Announces Appointment of Glenn P. Sblendorio as Chairman of the Boardhttps://www.pharmaradar360.com/article/novo-nordisk-advances-weight-loss-strategy-with-data-from-2-billion-chinese-biot-b14782ba85919245PharmaRadar360en2026-09-29T06:59:32.000ZNovo Nordisk advances weight-loss strategy with data from $2 billion Chinese biotech dealhttps://www.pharmaradar360.com/article/novo-nordisk-licenses-oral-glp-1-gip-dual-agonist-hrs-1596-from-hengrui-for-300m-d6b0b617d5198200PharmaRadar360en2026-09-29T06:53:58.000ZNovo Nordisk Licenses Oral GLP-1/GIP Dual Agonist HRS-1596 From Hengrui for $300Mhttps://www.pharmaradar360.com/article/newsgp-concern-over-removal-of-another-opioid-use-disorder-treatment-f04431281d5a67edPharmaRadar360en2026-09-29T06:50:15.000ZnewsGP - -Concern over removal of another opioid use disorder treatmenthttps://www.pharmaradar360.com/article/biotech-stock-kodiak-sciences-nasdaq-kod-leads-nasdaq-s-monday-gainers-up-177-f86c5cfa3809c826PharmaRadar360en2026-09-29T06:42:00.000ZBiotech Stock Kodiak Sciences (Nasdaq: KOD) Leads Nasdaq's Monday Gainers; up 177%https://www.pharmaradar360.com/article/lifecore-biomedical-nasdaq-lfcr-closes-up-on-acquisition-news-fba1237a0a39d2aePharmaRadar360en2026-09-29T06:42:00.000ZLifecore Biomedical (Nasdaq: LFCR) Closes up on Acquisition Newshttps://www.pharmaradar360.com/article/4d-150-gene-therapy-enters-phase-3-trial-for-diabetic-macular-edema-f2370ff796f12909PharmaRadar360en2026-09-29T06:38:58.000Z4D-150 Gene Therapy Enters Phase 3 Trial for Diabetic Macular Edemahttps://www.pharmaradar360.com/article/lundbeck-rejects-notion-that-us-move-is-a-cost-cutting-exercise-f2243005f25bf789PharmaRadar360en2026-09-29T06:29:41.000ZLundbeck rejects notion that US move is a cost-cutting exercisehttps://www.pharmaradar360.com/article/biotech-platform-opens-at-michelin-innovation-site-1c9df27129d4a8d0PharmaRadar360en2026-09-29T05:59:59.000ZBiotech platform opens at Michelin innovation sitehttps://www.pharmaradar360.com/article/south-korea-s-daewoong-pharmaceutical-opens-advanced-biopharmaceutical-plant-in-9a0b484d355cd27cPharmaRadar360en2026-09-29T05:55:00.000ZSouth Korea's Daewoong Pharmaceutical Opens Advanced Biopharmaceutical Plant in Songdo, Full Operations Set for This Yearhttps://www.pharmaradar360.com/article/celltrion-seeks-new-partners-clients-at-cphi-3b85e4a224762cc1PharmaRadar360en2026-09-29T05:27:25.000ZCelltrion seeks new partners, clients at CPHIhttps://www.pharmaradar360.com/article/fda-flagged-glp-1-vision-loss-signal-in-2025-but-u-s-ozempic-and-mounjaro-labels-e84561b015112018PharmaRadar360en2026-09-29T04:45:21.000ZFDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warninghttps://www.pharmaradar360.com/article/gazyva-wins-fda-approval-for-childhood-onset-nephrotic-c94a146d3363ef57PharmaRadar360en2026-09-29T04:30:22.000ZGazyva Wins FDA Approval for Childhood-Onset Nephrotic…https://www.pharmaradar360.com/article/mumbai-s-122-year-old-kyani-co-licence-suspended-what-tukaram-mundhe-s-team-foun-b58d094a972d9d96PharmaRadar360en2026-09-29T04:30:14.000ZMumbai’s 122-year-old Kyani & Co licence suspended: What Tukaram Mundhe’s team foundhttps://www.pharmaradar360.com/article/why-is-chugai-pharmaceutical-stock-sliding-today-45734eb66b0da808PharmaRadar360en2026-09-29T04:24:09.000ZWhy is Chugai Pharmaceutical stock sliding today?https://www.pharmaradar360.com/article/natco-pharma-pumps-more-funds-into-biotech-firm-egenesis-db200a009c181a15PharmaRadar360en2026-09-29T04:15:21.000ZNATCO Pharma pumps more funds into biotech firm eGenesishttps://www.pharmaradar360.com/article/new-eye-treatment-boosts-kodiak-into-ranks-of-resurgent-biotechs-c7a7c43b2069c544PharmaRadar360en2026-09-29T04:04:58.000ZNew Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechshttps://www.pharmaradar360.com/article/astrazeneca-makes-2-billion-strategic-equity-investment-in-summit-therapeutics-be875f0f9c059c38PharmaRadar360en2026-09-29T04:02:13.000ZAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeuticshttps://www.pharmaradar360.com/article/celltrion-to-seek-new-drug-cdmo-partners-at-int-l-pharmaceutical-exhibition-in-m-bd79197ebe74f80aPharmaRadar360en2026-09-29T04:01:03.000ZCelltrion to seek new drug, CDMO partners at int'l pharmaceutical exhibition in Milanhttps://www.pharmaradar360.com/article/us-exempts-select-indian-speciality-drugs-from-100-pharmaceutical-tariff-084ae2b59c60ff84PharmaRadar360en2026-09-29T03:53:06.000ZUS Exempts Select Indian Speciality Drugs From 100% Pharmaceutical Tariffhttps://www.pharmaradar360.com/article/hlb-pharmaceutical-hits-upper-limit-for-second-day-as-lyrfigtu-fda-approval-fuel-8624872ebdc983a2PharmaRadar360en2026-09-29T03:35:00.000ZHLB Pharmaceutical Hits Upper Limit for Second Day as Lyrfigtu FDA Approval Fuels Group Stock Rallyhttps://www.pharmaradar360.com/article/why-kodiak-sciences-skyrocketed-today-b8da1deb5a06ffd2PharmaRadar360en2026-09-29T03:00:21.000ZWhy Kodiak Sciences Skyrocketed Todayhttps://www.pharmaradar360.com/article/anzen-pmda-risk-communications-ibuprofen-l-lysine-etc-posted-9d9dac1d75cb338dPharmaRadar360en2026-09-29T03:00:00.000Z[ANZEN]PMDA Risk Communications: Ibuprofen L-Lysine,etc. postedhttps://www.pharmaradar360.com/article/anzen-revisions-of-precautions-azathioprine-etc-posted-423279923180d89fPharmaRadar360en2026-09-29T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Azathioprine, etc. postedhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-jivi-partial-change-approval-7ebc0317623b7b65PharmaRadar360en2026-09-29T03:00:00.000Z[SHINSA]English Translation of Review Report: Jivi (Partial Change Approval)https://www.pharmaradar360.com/article/fda-issues-recall-for-over-25-000-bottles-of-blood-pressure-medication-due-to-im-e6b1ebec1df57b71PharmaRadar360en2026-09-29T02:47:08.000ZFDA Issues Recall for Over 25,000 Bottles of Blood Pressure Medication Due to Improper Dissolutionhttps://www.pharmaradar360.com/article/the-new-weight-loss-drug-aabfe0db51fb65a7PharmaRadar360en2026-09-29T02:28:41.000Zthe new weight-loss drughttps://www.pharmaradar360.com/article/kod-stock-cracks-september-s-top-5-biotech-gainers-on-eye-drug-win-but-pharma-br-b156e8591040213bPharmaRadar360en2026-09-29T02:13:00.000ZKOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’https://www.pharmaradar360.com/article/merck-mrk-withdrew-a-cancer-filing-is-the-drug-s-promise-still-intact-5399ab24510ccde2PharmaRadar360en2026-09-29T02:11:28.000ZMerck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?https://www.pharmaradar360.com/article/reverse-mergers-rival-ipos-as-biotech-s-new-door-to-wall-street-says-biocentury-8e5856b3adc3cce4PharmaRadar360en2026-09-29T02:08:00.000ZReverse Mergers Rival IPOs as Biotech's New Door to Wall Street, Says BioCentury's Bonanoshttps://www.pharmaradar360.com/article/precigen-pgen-gets-fda-recognition-can-it-cut-the-cost-of-developing-new-drugs-b9602e5d49d92b62PharmaRadar360en2026-09-29T01:58:39.000ZPrecigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?https://www.pharmaradar360.com/article/astrazeneca-takes-2-billion-stake-in-summit-strong-endorsement-for-akeso-s-ivone-3e5b4cba86e6ba8ePharmaRadar360en2026-09-29T01:55:00.000ZAstraZeneca Takes $2 Billion Stake in Summit, Strong Endorsement for Akeso's Ivonescimab Global Developmenthttps://www.pharmaradar360.com/article/received-a-galaxy-watch-as-a-chuseok-gift-but-use-prohibited-for-under-22s-and-p-abcf98c72406ba53PharmaRadar360en2026-09-29T01:49:54.000ZReceived a Galaxy Watch as a Chuseok Gift, but Use Prohibited for Under 22s and Pregnant Women [Why&Next]https://www.pharmaradar360.com/article/fda-approves-juvmo-for-adult-parkinson-s-disease-a22407f17229b749PharmaRadar360en2026-09-29T01:32:49.000ZFDA Approves Juvmo for Adult Parkinson’s Diseasehttps://www.pharmaradar360.com/article/cambridge-sets-property-tax-rates-with-a-nervous-eye-on-commercial-sector-and-li-221f6469fe71bff9PharmaRadar360en2026-09-29T01:30:05.000ZCambridge sets property tax rates with a nervous eye on commercial sector and limp biotech markethttps://www.pharmaradar360.com/article/hlb-having-surpassed-cholangiocarcinoma-expected-to-resubmit-new-liver-cancer-dr-b373b13f43114d77PharmaRadar360en2026-09-29T00:50:13.000ZHLB, Having Surpassed Cholangiocarcinoma, Expected to Resubmit New Liver Cancer Drug Application to FDA Next Monthhttps://www.pharmaradar360.com/article/biotech-company-breaks-ground-on-hillsboro-facility-expansion-468689b1a89cdfa8PharmaRadar360en2026-09-29T00:37:00.000ZBiotech company breaks ground on Hillsboro facility expansionhttps://www.pharmaradar360.com/article/cellbion-wins-korea-nod-for-phase-3-prostate-cancer-drug-starts-trial-chosunbiz-d7b05be5bc9f6f65PharmaRadar360en2026-09-29T00:30:00.000ZCellBion wins Korea nod for phase 3 prostate cancer drug, starts trial - CHOSUNBIZhttps://www.pharmaradar360.com/article/from-brussels-sprouts-to-biotech-mahi-s-honors-thesis-success-story-commonwealth-a509f7808fbff0c1PharmaRadar360en2026-09-29T00:23:05.000ZFrom Brussels Sprouts to Biotech: Mahi's Honors Thesis Success Story : Commonwealth Honors Collegehttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-7addbe34b63161ccPharmaRadar360en2026-09-29T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-0139664b183e522cPharmaRadar360en2026-09-29T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-fbd2c412c210e2c4PharmaRadar360en2026-09-29T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-3553f0f4bf87a76ePharmaRadar360en2026-09-29T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-717e8db34803f504PharmaRadar360en2026-09-29T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-54f67761f41d9df9PharmaRadar360en2026-09-29T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-26d8d0469c4e287cPharmaRadar360en2026-09-29T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-af26f64403096f99PharmaRadar360en2026-09-29T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-9d6ebc69ec0a608dPharmaRadar360en2026-09-29T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-08fb835606b789daPharmaRadar360en2026-09-29T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-56a0175d02057f14PharmaRadar360en2026-09-29T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-c55bd056e92752fbPharmaRadar360en2026-09-29T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-7680bc6b18e6282cPharmaRadar360en2026-09-29T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-376e8bbd88f3cb18PharmaRadar360en2026-09-29T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-6733ab8454fb1b35PharmaRadar360en2026-09-29T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-h-af7f1ecb0cd2a025PharmaRadar360en2026-09-29T00:00:00.000ZMedicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; Other Policy Changes; and Adoption of Updated Versions ofhttps://www.pharmaradar360.com/article/determination-that-sulfadiazine-sulfadiazine-tablet-500-milligrams-was-not-withd-185ff7ee7a0b4c27PharmaRadar360en2026-09-29T00:00:00.000ZDetermination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-1fb58790d608d570PharmaRadar360en2026-09-29T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/fhta-llc-withdrawal-of-approval-of-new-drug-application-for-mysoline-primidone-s-0d8b67a07e21ea7fPharmaRadar360en2026-09-29T00:00:00.000ZFHTA LLC; Withdrawal of Approval of New Drug Application for MYSOLINE (Primidone) Suspension, 250 Milligrams/5 Millilitershttps://www.pharmaradar360.com/article/modification-of-living-organ-donation-reimbursement-program-eligibility-guidelin-b98e2cc78f5aeaddPharmaRadar360en2026-09-29T00:00:00.000ZModification of Living Organ Donation Reimbursement Program Eligibility Guidelines in Response To Honor Our Living Donors Acthttps://www.pharmaradar360.com/article/statement-of-organization-functions-and-delegations-of-authority-051f8053a1ff1646PharmaRadar360en2026-09-29T00:00:00.000ZStatement of Organization, Functions, and Delegations of Authorityhttps://www.pharmaradar360.com/article/aim-incarcerated-women-resource-kit-291b90e87db795d3PharmaRadar360en2026-09-29T00:00:00.000ZAIM Incarcerated Women Resource Kithttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-046b67f4789a0439PharmaRadar360en2026-09-29T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; National Marrow Donor Program Patient Support Center Surveyhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-5a355989d48083c6PharmaRadar360en2026-09-29T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food andhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pro-a900afbff61b0a18PharmaRadar360en2026-09-29T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boardshttps://www.pharmaradar360.com/article/angela-turner-brown-n-p-decision-and-order-50bc1fba2a574626PharmaRadar360en2026-09-29T00:00:00.000ZAngela Turner-Brown, N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/jt-medical-llc-decision-and-order-a279dffc15711cd2PharmaRadar360en2026-09-29T00:00:00.000ZJT Medical, LLC; Decision and Orderhttps://www.pharmaradar360.com/article/christopher-nadorff-m-d-decision-and-order-cf42037875999580PharmaRadar360en2026-09-29T00:00:00.000ZChristopher Nadorff, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/jorge-j-figueroa-m-d-decision-and-order-94e51e62df1ca611PharmaRadar360en2026-09-29T00:00:00.000ZJorge J. Figueroa, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/johann-farley-m-d-decision-and-order-c0839abbf63b06dfPharmaRadar360en2026-09-29T00:00:00.000ZJohann Farley, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/cleveland-clinic-london-appoints-dr-heather-shaw-as-oncology-vice-chief-9269d10544a63e18PharmaRadar360en2026-09-29T00:00:00.000ZCleveland Clinic London Appoints Dr Heather Shaw as Oncology Vice Chiefhttps://www.pharmaradar360.com/article/molecular-dynamics-analysis-of-the-na-taurocholate-cotransporting-polypeptide-nt-d4f8d12e229650afPharmaRadar360en2026-09-29T00:00:00.000ZMolecular dynamics analysis of the NA+- taurocholate cotransporting polypeptide (NTCP) in complex with the antiviral drug bulevirtidehttps://www.pharmaradar360.com/article/development-biomanufacturing-and-pilot-clinical-translation-of-an-allogeneic-msc-b70b64928cefe95fPharmaRadar360en2026-09-29T00:00:00.000ZDevelopment, biomanufacturing and pilot clinical translation of an allogeneic MSC-derived extracellular vesicle producthttps://www.pharmaradar360.com/article/drug-induced-postpartum-epigenetic-remodeling-of-dna-methylation-in-female-mice-324c73c609e7084ePharmaRadar360en2026-09-29T00:00:00.000ZDrug-induced postpartum epigenetic remodeling of DNA methylation in female mice following pregnancy and weaninghttps://www.pharmaradar360.com/article/postoperative-swelling-and-pain-following-impacted-mandibular-third-molar-surger-ff31f942d6eb6e13PharmaRadar360en2026-09-29T00:00:00.000ZPostoperative swelling and pain following impacted mandibular third molar surgeryhttps://www.pharmaradar360.com/article/monoclonal-antibody-based-cancer-therapy-from-mechanistic-insights-to-clinical-p-24dda6590efa1d9ePharmaRadar360en2026-09-29T00:00:00.000ZMonoclonal Antibody-Based Cancer Therapy: From Mechanistic Insights to Clinical Practicehttps://www.pharmaradar360.com/article/autologous-adipose-derived-stem-cell-therapy-in-orthopedic-surgery-current-conce-3629197924cd6467PharmaRadar360en2026-09-29T00:00:00.000ZAUTOLOGOUS ADIPOSE-DERIVED STEM CELL THERAPY IN ORTHOPEDIC SURGERY: CURRENT CONCEPTS AND CLINICAL APPLICATIONShttps://www.pharmaradar360.com/article/machine-learning-and-natural-language-processing-for-mental-health-detection-in-7de4e697bae4fe4cPharmaRadar360en2026-09-29T00:00:00.000ZMachine Learning and Natural Language Processing for Mental Health Detection in Clinical Text: A Scoping Reviewhttps://www.pharmaradar360.com/article/exact-solutions-of-higher-dimensional-integrable-models-using-extended-trial-fun-9f8627d058275e77PharmaRadar360en2026-09-29T00:00:00.000ZExact Solutions of Higher-Dimensional Integrable Models Using Extended Trial Functions Within a Symbolic Neural Network Computationhttps://www.pharmaradar360.com/article/association-of-age-related-macular-degeneration-and-dementia-a-health-registry-d-da79fb142cf0e825PharmaRadar360en2026-09-29T00:00:00.000ZAssociation of Age-Related Macular Degeneration and Dementia: A Health Registry Database Studyhttps://www.pharmaradar360.com/article/comment-on-akkaya-et-al-posterior-teflon-felt-reinforced-coronary-button-anastom-bc225b5b033c0648PharmaRadar360en2026-09-29T00:00:00.000ZComment on Akkaya et al. Posterior Teflon-Felt-Reinforced Coronary Button Anastomosis in a Modified Bentall Procedure: Early Outcomes in a Single-Center Retrospective Study. J. Clin. Med. 2026, 15, 2546https://www.pharmaradar360.com/article/case-series-adhd-phenotype-in-a-family-with-npy-gene-microduplication-41e4bc5b0eb81bc7PharmaRadar360en2026-09-29T00:00:00.000ZCase Series: ADHD Phenotype in a Family with NPY Gene Microduplicationhttps://www.pharmaradar360.com/article/human-ipsc-derived-brain-cells-organoids-and-organoids-on-chips-advancing-neurol-c56d370d49bdc735PharmaRadar360en2026-09-29T00:00:00.000ZHuman iPSC-Derived Brain Cells, Organoids, and Organoids-on-Chips: Advancing Neurological Disease Modeling to Improve Clinical Outcomehttps://www.pharmaradar360.com/article/long-term-clinical-experience-with-a-3-step-combined-technique-for-involutional-3e27f204cb551906PharmaRadar360en2026-09-29T00:00:00.000ZLong-term clinical experience with a 3-step combined technique for involutional lower eyelid entropion and ectropion based on common pathophysiologic mechanismshttps://www.pharmaradar360.com/article/building-recovery-capital-co-creating-an-assets-based-community-engagement-toolk-2ea5245506606226PharmaRadar360en2026-09-29T00:00:00.000ZBuilding recovery capital: co-creating an assets-based community engagement toolkit for people accessing drug and alcohol treatment serviceshttps://www.pharmaradar360.com/article/study-on-the-operational-efficiency-of-clinical-departments-in-a-grade-iii-gener-f5666d7fc6fbd828PharmaRadar360en2026-09-29T00:00:00.000ZStudy on the operational efficiency of clinical departments in a Grade III general hospitalhttps://www.pharmaradar360.com/article/cannabinoids-in-oncology-pharmacology-clinical-applications-and-translational-pe-a876903a36af261aPharmaRadar360en2026-09-29T00:00:00.000ZCannabinoids in oncology: pharmacology, clinical applications, and translational perspectiveshttps://www.pharmaradar360.com/article/efficacy-and-specific-toxicity-profiles-of-gprc5d-versus-bcma-targeted-bispecifi-4f5aea8b6e28a7c8PharmaRadar360en2026-09-29T00:00:00.000ZEfficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studieshttps://www.pharmaradar360.com/article/high-fat-diet-and-portal-hypertension-a-triangulation-approach-combining-mendeli-d42a027885b1fe3aPharmaRadar360en2026-09-29T00:00:00.000ZHigh-fat diet and portal hypertension: a triangulation approach combining Mendelian randomization with retrospective clinical analysishttps://www.pharmaradar360.com/article/fire-dragon-cupping-therapy-for-primary-dysmenorrhea-a-systematic-review-of-avai-5407218f4f1eba70PharmaRadar360en2026-09-29T00:00:00.000ZFire dragon cupping therapy for primary dysmenorrhea: a systematic review of available clinical evidence and research gapshttps://www.pharmaradar360.com/article/reading-discordant-bedside-indices-in-sepsis-induced-cardiomyopathy-an-evidence-b1de8ce815dc7bf8PharmaRadar360en2026-09-29T00:00:00.000ZReading discordant bedside indices in sepsis-induced cardiomyopathy: an evidence-mapping framework for diagnosis and trial designhttps://www.pharmaradar360.com/article/evolution-of-therapeutic-approaches-to-atopic-dermatitis-a-comparative-analysis-45e085b8fefc56bdPharmaRadar360en2026-09-29T00:00:00.000ZEVOLUTION OF THERAPEUTIC APPROACHES TO ATOPIC DERMATITIS: A COMPARATIVE ANALYSIS OF CURRENT CLINICAL GUIDELINEShttps://www.pharmaradar360.com/article/clinical-phenotypes-of-bronchopulmonary-dysplasia-implications-for-diagnosis-and-83faec694079c3ccPharmaRadar360en2026-09-29T00:00:00.000ZCLINICAL PHENOTYPES OF BRONCHOPULMONARY DYSPLASIA: IMPLICATIONS FOR DIAGNOSIS AND TREATMENThttps://www.pharmaradar360.com/article/concentration-of-stress-associated-neurotransmitters-in-the-oral-fluid-of-childr-de0ab989429db0ffPharmaRadar360en2026-09-29T00:00:00.000ZCONCENTRATION OF STRESS-ASSOCIATED NEUROTRANSMITTERS IN THE ORAL FLUID OF CHILDREN WITH VARYING CLINICAL STATUS OF DENTAL HARD TISSUE IN RELATION TO REACTIVE ANXIETY LEVELS AND THE FORCED DISPLACEMENT FACTORhttps://www.pharmaradar360.com/article/gastric-subepithelial-lesions-as-a-complex-clinical-problem-examples-of-the-effe-9f98a17f1937460ePharmaRadar360en2026-09-29T00:00:00.000ZGastric subepithelial lesions as a complex clinical problem. Examples of the effectiveness of endoscopic ultrasound diagnosticshttps://www.pharmaradar360.com/article/integrated-machine-learning-and-structure-based-computational-prioritization-of-4499ef61c3cb1dc9PharmaRadar360en2026-09-29T00:00:00.000ZIntegrated Machine Learning and Structure-Based Computational Prioritization of KIF11 Inhibitor Candidates for CNS-Oriented Drug Discoveryhttps://www.pharmaradar360.com/article/deterministic-fact-validation-for-retrieval-augmented-generation-of-clinical-dat-a104044696c232c3PharmaRadar360en2026-09-29T00:00:00.000ZDeterministic Fact Validation for Retrieval-Augmented Generation of Clinical Data Reviewer's Guides: A Proposed Architecturehttps://www.pharmaradar360.com/article/who-carries-the-load-role-specific-cognitive-load-and-team-performance-in-a-mult-0547e994b605015bPharmaRadar360en2026-09-29T00:00:00.000ZWho carries the load? Role-specific cognitive load and team performance in a multi-role virtual reality emergency simulation: an exploratory pilot study of collaborative clinical reasoning in undergraduate medical educationhttps://www.pharmaradar360.com/article/making-foundational-clinical-integration-visible-an-exploratory-mixed-methods-co-57349a44494eeba0PharmaRadar360en2026-09-29T00:00:00.000ZMaking foundational-clinical integration visible: an exploratory mixed-methods course evaluation of the BASIC tutorial modelhttps://www.pharmaradar360.com/article/phenol-matrixectomy-in-pregnancy-and-breastfeeding-correction-of-exposure-calcul-b8c9722de86781e0PharmaRadar360en2026-09-29T00:00:00.000ZPhenol Matrixectomy in Pregnancy and Breastfeeding: Correction of Exposure Calculations and Implications for Clinical Risk Assessmenthttps://www.pharmaradar360.com/article/metabolically-controlled-oncological-treatment-an-evidence-graded-framework-inte-00cd332886178810PharmaRadar360en2026-09-29T00:00:00.000ZMetabolically Controlled Oncological Treatment: An Evidence-Graded Framework Integrating Metabolic Reprogramming, Targeted Drug Delivery, and Standard Oncological Carehttps://www.pharmaradar360.com/article/klinicka-prezentacija-tumora-sredisnjeg-zivcanog-sustava-u-djecjoj-dobi-prikaz-s-fd0475bb9d67c2a7PharmaRadar360en2026-09-29T00:00:00.000ZKlinička prezentacija tumora središnjeg živčanog sustava u dječjoj dobi - prikaz slučajevahttps://www.pharmaradar360.com/article/next-generation-car-t-cell-therapy-against-cancer-precision-engineering-programm-d9bbbbf7fed4fe19PharmaRadar360en2026-09-29T00:00:00.000ZNext-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiershttps://www.pharmaradar360.com/article/lymphopenia-and-elevated-nlr-identify-patients-with-septic-shock-who-may-benefit-69404f4f671a72bbPharmaRadar360en2026-09-29T00:00:00.000ZLymphopenia and elevated NLR identify patients with septic shock who may benefit from corticosteroids: a target trial emulation studyhttps://www.pharmaradar360.com/article/a-fixed-not-proportional-cycling-treadmill-heart-rate-bias-at-the-ventilatory-th-00a0486da8dd91c4PharmaRadar360en2026-09-29T00:00:00.000ZA fixed, not proportional, cycling–treadmill heart rate bias at the ventilatory thresholds: a randomized crossover trialhttps://www.pharmaradar360.com/article/disitamab-vedotin-triggers-ferroptosis-to-activate-cd8-t-cell-antitumor-immunity-53f22e636c3dbd8bPharmaRadar360en2026-09-29T00:00:00.000ZDisitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancerhttps://www.pharmaradar360.com/article/effect-of-a-nurse-led-hospital-to-home-digital-health-transition-program-on-heal-027b9582af894950PharmaRadar360en2026-09-29T00:00:00.000ZEffect of a nurse-led hospital to home digital health transition program on health outcomes and caregiver burden after CABG: a parallel randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-ai-and-vr-supported-multicomponent-learning-intervention-configuratio-ab85f9c191393370PharmaRadar360en2026-09-29T00:00:00.000ZEffects of AI- and VR-supported multicomponent learning intervention configurations on supervisor-rated feedback-literacy behaviors in medical students: a randomized controlled trialhttps://www.pharmaradar360.com/article/effect-of-a-medical-checklist-on-performance-in-a-tricyclic-antidepressant-poiso-82bb19d2900e6637PharmaRadar360en2026-09-29T00:00:00.000ZEffect of a medical checklist on performance in a tricyclic antidepressant poisoning scenario: a simulation-based randomized controlled trialhttps://www.pharmaradar360.com/article/intratracheal-budesonide-combined-with-surfactant-for-respiratory-distress-syndr-2f3dcde3ba28eda4PharmaRadar360en2026-09-29T00:00:00.000ZIntratracheal budesonide combined with surfactant for respiratory distress syndrome in preterm infants: A randomized clinical trialhttps://www.pharmaradar360.com/article/primary-and-secondary-raynaud-a-scientific-statement-from-the-american-heart-ass-1376d145f3b2b25bPharmaRadar360en2026-09-29T00:00:00.000ZPrimary and Secondary Raynaud: A Scientific Statement From the American Heart Associationhttps://www.pharmaradar360.com/article/scp-hiv-scp-associated-nephropathy-a-decade-of-clinical-outcomes-global-disparit-8193a0f8bd6060d2PharmaRadar360en2026-09-29T00:00:00.000Z<scp>HIV</scp> ‐associated nephropathy: A decade of clinical outcomes, global disparities and emerging promisehttps://www.pharmaradar360.com/article/clinical-value-of-real-time-three-dimensional-echocardiography-for-evaluating-ri-cffa2afe7cac1400PharmaRadar360en2026-09-29T00:00:00.000ZClinical Value of Real‐Time Three‐Dimensional Echocardiography for Evaluating Right Ventricular Structure and Function in Patients With Pulmonary Hypertension Across Different Echocardiographic Pulmonary Artery Systolic Pressure Stratahttps://www.pharmaradar360.com/article/harnessing-quantitative-medicine-to-advance-oncology-drug-development-f9e65099d281bd27PharmaRadar360en2026-09-29T00:00:00.000ZHarnessing Quantitative Medicine to Advance Oncology Drug Developmenthttps://www.pharmaradar360.com/article/adoption-of-ai-enabled-features-in-e-pharmacies-and-their-impact-on-consumer-dec-4e9b5067e925573ePharmaRadar360en2026-09-29T00:00:00.000ZAdoption of AI-enabled features in e-pharmacies and their impact on consumer decision-making and purchase intention in Indiahttps://www.pharmaradar360.com/article/ps12-28-a-gut-environment-modifier-in-antibiotic-treated-dairy-heifer-calves-wit-ffa130a35011cd5aPharmaRadar360en2026-09-29T00:00:00.000ZPS12-28. A Gut Environment Modifier in Antibiotic Treated Dairy Heifer Calves with Clinical Digestive or Respiratory Disease.https://www.pharmaradar360.com/article/126-comparative-genomics-of-fusobacterium-necrophorum-reveals-subspecies-specifi-1ed400d00925481bPharmaRadar360en2026-09-29T00:00:00.000Z126. Comparative Genomics of Fusobacterium Necrophorum Reveals Subspecies-specific Antimicrobial Resistance Gene Patterns and Virulence Factor Distribution Across Bovine and Human Clinical Isolates.https://www.pharmaradar360.com/article/managing-urinary-tract-infections-in-pregnancy-teratogenic-risks-molecular-mecha-fb600c16ee738b69PharmaRadar360en2026-09-29T00:00:00.000ZManaging Urinary tract infections in pregnancy: teratogenic risks, molecular mechanisms, and antibiotic safetyhttps://www.pharmaradar360.com/article/preparation-and-i-in-vitro-i-evaluation-of-amphotericin-b-chondroitin-sulfate-po-67ac2740a793f501PharmaRadar360en2026-09-29T00:00:00.000ZPreparation and <i>in vitro</i> evaluation of amphotericin B-chondroitin sulfate polymer prodrughttps://www.pharmaradar360.com/article/circnfix-attenuates-acute-kidney-injury-by-driving-m6a-dependent-degradation-of-9703e91e6c437ef7PharmaRadar360en2026-09-29T00:00:00.000ZcircNfix attenuates acute kidney injury by driving m6A-dependent degradation of YTHDF2 to stabilize DAPK2 mRNAhttps://www.pharmaradar360.com/article/end-of-induction-circulating-tumor-dna-outperforms-conventional-cellular-mrd-for-aa052718aa6bac7cPharmaRadar360en2026-09-29T00:00:00.000ZEnd-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trialhttps://www.pharmaradar360.com/article/yiqi-guben-capsule-alleviates-asthmatic-airway-inflammation-through-the-mir-34a-72e4fbbf830c868ePharmaRadar360en2026-09-29T00:00:00.000ZYiqi Guben capsule alleviates asthmatic airway inflammation through the miR-34a-5p/Notch1 pathway associated with Treg/Th17 immune balancehttps://www.pharmaradar360.com/article/current-status-of-animal-models-for-premature-ovarian-insufficiency-similarities-f6bce19d9e93a6aePharmaRadar360en2026-09-29T00:00:00.000ZCurrent Status of Animal Models for Premature Ovarian Insufficiency: Similarities to Clinical Manifestations and Therapeutic Applicationshttps://www.pharmaradar360.com/article/rapid-intracystic-growth-of-spindle-cell-type-anaplastic-carcinoma-derived-from-e8293e3cfa0a5e31PharmaRadar360en2026-09-29T00:00:00.000ZRapid intracystic growth of spindle cell-type anaplastic carcinoma derived from intraductal papillary mucinous carcinomahttps://www.pharmaradar360.com/article/digital-self-management-engagement-and-long-term-patient-reported-outcome-trajec-0c697dee8f2ac0ddPharmaRadar360en2026-09-29T00:00:00.000ZDigital self-management engagement and long-term patient-reported outcome trajectories in inflammatory arthritis: a real-world retrospective cohort studyhttps://www.pharmaradar360.com/article/pupil-size-measurements-with-two-multifunctional-devices-based-on-different-tech-12b21e1ed02546ddPharmaRadar360en2026-09-29T00:00:00.000ZPupil size measurements with two multifunctional devices based on different technologies and an infrared based pupillometerhttps://www.pharmaradar360.com/article/a-practical-guide-to-optimal-adaptive-two-stage-designs-for-various-endpoint-typ-3ad619688f1da475PharmaRadar360en2026-09-29T00:00:00.000ZA Practical Guide to Optimal Adaptive Two‐Stage Designs for Various Endpoint Typeshttps://www.pharmaradar360.com/article/scp-beacon-scp-an-adaptive-bayesian-early-phase-oncology-trial-design-integratin-db3f520cdaac9992PharmaRadar360en2026-09-29T00:00:00.000Z<scp>BEACON</scp> : An Adaptive Bayesian Early‐Phase Oncology Trial Design Integrating Dose Optimization and Proof‐of‐Concept Across Survival and Binary Endpointshttps://www.pharmaradar360.com/article/issue-information-6b2fb90d34ac3cc1PharmaRadar360en2026-09-29T00:00:00.000ZIssue Informationhttps://www.pharmaradar360.com/article/multiple-primary-malignancies-involving-papillary-thyroid-carcinoma-a-three-case-0db9d6c498a23f94PharmaRadar360en2026-09-29T00:00:00.000ZMultiple Primary Malignancies Involving Papillary Thyroid Carcinoma: A Three‐Case Serieshttps://www.pharmaradar360.com/article/pharmacoeconomics-and-outcomes-research-redefining-value-in-the-era-of-therapeut-c5f21244701e9bcbPharmaRadar360en2026-09-29T00:00:00.000ZPharmacoeconomics and outcomes research: Redefining value in the era of therapeutic innovation—Editorialhttps://www.pharmaradar360.com/article/students-explore-biotech-careers-at-boston-life-science-event-ab30dbfe92789b09PharmaRadar360en2026-09-28T23:39:28.000ZStudents explore biotech careers at Boston life science eventhttps://www.pharmaradar360.com/article/manufacturing-intelligence-what-fda-s-nam-rule-means-for-cmc-teams-c2867ad7219b3bb8PharmaRadar360en2026-09-28T23:32:35.000ZManufacturing Intelligence: What FDA's NAM Rule Means for CMC Teamshttps://www.pharmaradar360.com/article/biotech-and-small-cap-healthcare-stocks-jumped-on-big-news-a73376e7745e2fa0PharmaRadar360en2026-09-28T22:13:45.000ZBiotech And Small-Cap Healthcare Stocks Jumped On Big Newshttps://www.pharmaradar360.com/article/a-rare-disorder-can-cause-severe-seizures-in-babies-medicure-s-study-has-enrolle-16abf838f0a8a523PharmaRadar360en2026-09-28T22:00:00.000ZA rare disorder can cause severe seizures in babies. Medicure's study has enrolled 10 patients.https://www.pharmaradar360.com/article/fda-confirmation-hearing-gives-update-on-abortion-pill-study-under-new-leadershi-98c78a37d9ea1e98PharmaRadar360en2026-09-28T21:42:31.000ZFDA Confirmation Hearing Gives Update on Abortion Pill Study Under New Leadershiphttps://www.pharmaradar360.com/article/liquidia-rises-8-amid-broader-strength-in-biotech-peers-lqda-nasdaq-b4453a94f1c49c2aPharmaRadar360en2026-09-28T21:26:09.000ZLiquidia rises 8% amid broader strength in biotech peers (LQDA:NASDAQ)https://www.pharmaradar360.com/article/stocks-jump-on-clinical-trial-updates-acquisition-deals-and-trading-momentum-567e9bf3f4ebf614PharmaRadar360en2026-09-28T21:25:16.000ZStocks jump on clinical trial updates, acquisition deals, and trading momentum.https://www.pharmaradar360.com/article/helix-biopharma-strengthens-biotech-leadership-and-corporate-governance-through-807d2e47216e3491PharmaRadar360en2026-09-28T21:21:03.000ZHelix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned Board Changeshttps://www.pharmaradar360.com/article/merck-pays-400m-for-cancer-drug-prospect-from-china-based-scibrunch-a745f6a8b602bdcfPharmaRadar360en2026-09-28T20:33:55.000ZMerck Pays $400M for Cancer Drug Prospect From China-Based SciBrunchhttps://www.pharmaradar360.com/article/cphi-milan-2026-digital-supply-chains-c64d6379262b3e0cPharmaRadar360en2026-09-28T20:13:13.000ZCPHI Milan 2026: Digital Supply Chainshttps://www.pharmaradar360.com/article/fda-approves-abbvie-s-juvmo-for-parkinson-disease-4b2069afce3cb89dPharmaRadar360en2026-09-28T20:12:13.000ZFDA Approves AbbVie's Juvmo for Parkinson Diseasehttps://www.pharmaradar360.com/article/merck-acquires-spr2015-in-2-13-billion-licensing-deal-pharmexec-c924cc42a243eee9PharmaRadar360en2026-09-28T20:00:43.000ZMerck Acquires SPR2015 in $2.13 Billion Licensing Deal | PharmExechttps://www.pharmaradar360.com/article/fda-approves-a-medicine-to-help-prevent-bone-complications-in-adults-whose-cance-e80e448af4fb7e44PharmaRadar360en2026-09-28T20:00:00.000ZFDA approves a medicine to help prevent bone complications in adults whose cancer has spread to bonehttps://www.pharmaradar360.com/article/gs1-us-introduces-best-practice-guidance-for-pharmaceutical-saleable-returns-b558dcb7e27c13dbPharmaRadar360en2026-09-28T19:47:15.000ZGS1 US Introduces Best Practice Guidance for Pharmaceutical Saleable Returnshttps://www.pharmaradar360.com/article/can-abbvie-s-backing-help-adarx-win-over-biotech-ipo-investors-at-a-1-74-billion-2b0a48eb28477c96PharmaRadar360en2026-09-28T19:39:16.000ZCan AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?https://www.pharmaradar360.com/article/fda-approves-tavapadon-for-the-treatment-of-parkinson-disease-b9bbaaaad4077fc7PharmaRadar360en2026-09-28T18:25:30.000ZFDA Approves Tavapadon for the Treatment of Parkinson Diseasehttps://www.pharmaradar360.com/article/micro-rmm-in-depth-focus-dc20160d4995f131PharmaRadar360en2026-09-28T18:15:57.000ZMicro/RMM In-Depth Focushttps://www.pharmaradar360.com/article/alarming-recall-hits-13-567-bottles-is-yours-one-of-them-7c9fed280c6dea86PharmaRadar360en2026-09-28T17:29:12.000ZAlarming recall hits 13,567 bottles. Is yours one of them?https://www.pharmaradar360.com/article/more-than-representation-why-we-belong-in-clinical-research-3e911ee5c133bc18PharmaRadar360en2026-09-28T17:16:38.000ZMore Than Representation: Why We Belong in Clinical Researchhttps://www.pharmaradar360.com/article/josh-hawley-says-fda-turned-every-mailbox-into-a-planned-parenthood-84c7d9aca4753548PharmaRadar360en2026-09-28T17:04:00.000ZJosh Hawley says FDA turned 'every mailbox into a Planned Parenthood'https://www.pharmaradar360.com/article/deruxtecan-deja-vu-b21c8fbce9c1cecfPharmaRadar360en2026-09-28T16:54:18.000ZDeruxtecan déjà vuhttps://www.pharmaradar360.com/article/mumbai-fda-suspends-licence-of-kyani-co-over-food-safety-violations-58b40c77451e0eccPharmaRadar360en2026-09-28T16:44:08.000ZMumbai: FDA Suspends Licence of Kyani & Co Over Food Safety Violationshttps://www.pharmaradar360.com/article/cold-chain-consolidation-continues-as-eutecma-acquires-tempaid-229599bab20a540aPharmaRadar360en2026-09-28T16:33:50.000ZCold Chain Consolidation Continues as Eutecma Acquires Tempaidhttps://www.pharmaradar360.com/article/cordis-project-multiscale-simulations-of-hiv-capsid-assembly-and-rna-0c0d3c13f14f85e6PharmaRadar360en2026-09-28T16:31:57.000ZCORDIS project: Multiscale Simulations of HIV capsid assembly and RNAhttps://www.pharmaradar360.com/article/cordis-project-gate2brain-medicines-beyond-barriers-f75d8dc6ae42f9f8PharmaRadar360en2026-09-28T16:31:40.000ZCORDIS project: Gate2Brain. Medicines beyond barriers.https://www.pharmaradar360.com/article/cordis-project-training-for-innovative-research-in-cardiovascular-science-and-te-5287fd89111daf91PharmaRadar360en2026-09-28T16:31:36.000ZCORDIS project: Training for innOvative Research in Cardiovascular science and tecHnologyhttps://www.pharmaradar360.com/article/cordis-project-dataroc-the-ai-generated-and-powered-digital-twin-to-accelerate-h-cac5789852dd9c4fPharmaRadar360en2026-09-28T16:31:00.000ZCORDIS project: DataROC, the AI generated and powered digital twin to accelerate Health Sciencehttps://www.pharmaradar360.com/article/cordis-project-single-dose-cure-of-falciparum-malaria-using-next-generation-comb-06c2a0d77c3cdf35PharmaRadar360en2026-09-28T16:30:44.000ZCORDIS project: SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONShttps://www.pharmaradar360.com/article/kodiak-skyrockets-on-positive-study-data-for-2-eye-drugs-18ecc1261816c3f9PharmaRadar360en2026-09-28T16:14:32.000ZKodiak skyrockets on positive study data for 2 eye drugshttps://www.pharmaradar360.com/article/axios-live-biotech-experts-want-u-s-policy-to-keep-pace-with-innovation-d317fcc114e40664PharmaRadar360en2026-09-28T16:06:59.000ZAxios Live: Biotech experts want U.S. policy to keep pace with innovationhttps://www.pharmaradar360.com/article/cordis-project-cervical-cancers-escaping-hpv-screening-decoding-hpv-independent-307e4beeac9c75dfPharmaRadar360en2026-09-28T16:04:41.000ZCORDIS project: Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profilinghttps://www.pharmaradar360.com/article/gene-silencing-biotech-adarx-makes-some-noise-with-535m-stock-market-debut-a0ac421f0431de0bPharmaRadar360en2026-09-28T16:00:00.000ZGene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debuthttps://www.pharmaradar360.com/article/fda-approves-olumiant-for-adolescents-with-severe-alopecia-areata-e23cf93157e4c41bPharmaRadar360en2026-09-28T15:57:12.000ZFDA Approves Olumiant for Adolescents With Severe Alopecia Areatahttps://www.pharmaradar360.com/article/lawmakers-examine-challenges-facing-u-s-generic-drug-manufacturing-abe72f0b18e3bd4dPharmaRadar360en2026-09-28T15:55:46.000ZLawmakers Examine Challenges Facing U.S. Generic Drug Manufacturinghttps://www.pharmaradar360.com/article/hyperfine-names-roots-pharmaceutical-as-distributor-in-kuwait-and-uae-b78666bc753eab24PharmaRadar360en2026-09-28T15:42:08.000ZHyperfine names Roots Pharmaceutical as distributor in Kuwait and UAEhttps://www.pharmaradar360.com/article/india-secures-us-tariff-relief-for-specialty-pharmaceutical-products-93b38d894320a912PharmaRadar360en2026-09-28T15:36:51.000ZIndia Secures US Tariff Relief for Specialty Pharmaceutical Productshttps://www.pharmaradar360.com/article/mirum-s-liver-infection-drug-lowers-virus-levels-in-late-stage-study-e34f5887ee82a80ePharmaRadar360en2026-09-28T15:26:49.000ZMirum's liver infection drug lowers virus levels in late-stage studyhttps://www.pharmaradar360.com/article/china-s-lianya-pharmaceutical-sees-0-025-winning-rate-in-chinext-ipo-lottery-onl-9b9b0de2ab0b9bf8PharmaRadar360en2026-09-28T15:25:00.000ZChina's Lianya Pharmaceutical sees 0.025% winning rate in ChiNext IPO lottery; online subscription freezes over 12 trillion yuanhttps://www.pharmaradar360.com/article/three-women-say-they-almost-died-because-of-fda-approved-drug-06562f95ae61a366PharmaRadar360en2026-09-28T15:24:17.000ZThree women say they almost died because of FDA-approved drughttps://www.pharmaradar360.com/article/kodiak-sciences-soars-141-on-truly-impressive-pivotal-wet-amd-trial-win-1d1d94207521af1fPharmaRadar360en2026-09-28T15:21:08.000ZKodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Winhttps://www.pharmaradar360.com/article/abbvie-wins-fda-approval-for-parkinson-s-drug-from-8-7b-cerevel-takeover-92df3be2ca5e5d8aPharmaRadar360en2026-09-28T15:19:48.000ZAbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeoverhttps://www.pharmaradar360.com/article/kras-g12d-inhibitor-s-2-13b-deal-tests-cross-border-tech-transfer-e8dbdf94ae0793b8PharmaRadar360en2026-09-28T15:13:07.000ZKRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transferhttps://www.pharmaradar360.com/article/roche-drops-muscle-sparing-obesity-antibody-after-flunked-interim-analysis-a63e70285ee4cf92PharmaRadar360en2026-09-28T15:03:15.000ZRoche drops muscle-sparing obesity antibody after flunked interim analysishttps://www.pharmaradar360.com/article/lakewood-amedex-reports-positive-nu-3-mic-data-against-diabetic-foot-ulcer-clini-e7ce9a58b0bd3cb0PharmaRadar360en2026-09-28T14:57:47.000ZLakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolateshttps://www.pharmaradar360.com/article/rat-droppings-flies-roaches-tukaram-mundhe-s-team-shuts-mumbai-s-122-year-old-ky-22590cb6253a31ccPharmaRadar360en2026-09-28T14:49:19.000ZRat droppings, flies, roaches: Tukaram Mundhe's team shuts Mumbai's 122-year-old Kyani cafehttps://www.pharmaradar360.com/article/oncolytics-biotech-oncy-advances-clinical-trial-for-metastatic-colorectal-cancer-27aa93b793cf0ea2PharmaRadar360en2026-09-28T14:29:12.000ZOncolytics Biotech (ONCY) Advances Clinical Trial for Metastatic Colorectal Cancer Pelareorep Treatmenthttps://www.pharmaradar360.com/article/what-comes-next-for-west-pharmaceutical-services-nyse-wst-31a7da9591d54845PharmaRadar360en2026-09-28T14:27:00.000ZWhat Comes Next for West Pharmaceutical Services (NYSE:WST)?https://www.pharmaradar360.com/article/4d-molecular-therapeutics-initiates-patient-enrollment-in-phase-3-4sight-trial-f-f0f88a02cc99d741PharmaRadar360en2026-09-28T14:25:05.000Z4D Molecular Therapeutics Initiates Patient Enrollment in Phase 3 4SIGHT Trial for Diabetic Macular Edemahttps://www.pharmaradar360.com/article/michigan-attorney-tipped-family-about-pharmaceutical-companies-merger-sec-says-3ef1d39a2d396e48PharmaRadar360en2026-09-28T14:20:00.000ZMichigan attorney tipped family about pharmaceutical companies' merger, SEC sayshttps://www.pharmaradar360.com/article/leeds-review-sets-out-terms-of-reference-for-investigation-24ec70d5c42d1deaPharmaRadar360en2026-09-28T14:18:00.000ZLeeds review sets out terms of reference for investigationhttps://www.pharmaradar360.com/article/cdsco-seeks-to-strengthen-oversight-of-medicines-containing-narcotic-psychotropi-46a0e2d5eb7bdd85PharmaRadar360en2026-09-28T14:15:06.000ZCDSCO Seeks to Strengthen Oversight of Medicines Containing Narcotic, Psychotropic Substanceshttps://www.pharmaradar360.com/article/warum-der-blick-auf-medikamentenkosten-zu-kurz-greift-7a4051aab280f2c4PharmaRadar360en2026-09-28T14:14:48.000ZWarum der Blick auf Medikamentenkosten zu kurz greifthttps://www.pharmaradar360.com/article/this-biotech-company-added-nearly-3b-to-its-market-cap-here-s-why-kod-stock-is-r-0db7b4c3e818a3c8PharmaRadar360en2026-09-28T14:14:19.000ZThis Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Todayhttps://www.pharmaradar360.com/article/kodiak-sciences-says-eye-drug-on-par-with-regeneron-s-medicine-64599d833f273530PharmaRadar360en2026-09-28T14:05:22.000ZKodiak Sciences Says Eye Drug on Par with Regeneron's Medicinehttps://www.pharmaradar360.com/article/fda-upgrades-recall-of-blood-pressure-meds-distributed-nationwide-4d6b886a3b8a9b5aPharmaRadar360en2026-09-28T14:03:44.000ZFDA upgrades recall of blood pressure meds distributed nationwidehttps://www.pharmaradar360.com/article/novadip-biosciences-raises-10-4m-to-advance-clinical-trials-f7b0edcc936af5bcPharmaRadar360en2026-09-28T14:00:26.000ZNovadip Biosciences Raises €10.4M to Advance Clinical Trialshttps://www.pharmaradar360.com/article/oncolytics-biotech-inc-7d2b3c7e78dd55d6PharmaRadar360en2026-09-28T14:00:00.000ZOncolytics Biotech Inchttps://www.pharmaradar360.com/article/neonc-technologies-announces-fda-end-of-phase-1-meeting-for-neo212-ae07833ccffd4019PharmaRadar360en2026-09-28T13:59:10.000ZNeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212https://www.pharmaradar360.com/article/women-who-regret-abortion-pill-urge-change-from-trump-nominee-3392ff7c0f6e3017PharmaRadar360en2026-09-28T13:52:00.000ZWomen Who Regret Abortion Pill Urge Change From Trump Nomineehttps://www.pharmaradar360.com/article/abbvie-wins-fda-nod-for-parkinson-s-pill-f4a6259ff8aa21b4PharmaRadar360en2026-09-28T13:44:59.000ZAbbVie wins FDA nod for Parkinson’s pillhttps://www.pharmaradar360.com/article/lib-therapeutics-and-sun-pharma-announce-global-licensing-commercialization-and-690ffccb3e554a00PharmaRadar360en2026-09-28T13:43:19.000ZLIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EUhttps://www.pharmaradar360.com/article/oncolytics-biotech-announces-progress-in-reo-033-trial-site-activations-and-fda-bb2648098477d3e8PharmaRadar360en2026-09-28T13:40:00.000ZOncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal Cancerhttps://www.pharmaradar360.com/article/kenya-to-manufacture-new-once-monthly-hiv-prevention-pill-key-things-to-know-abo-fe80c895e2923ff3PharmaRadar360en2026-09-28T13:38:47.000ZKenya to manufacture new once-monthly HIV prevention pill: Key things to know about this dealhttps://www.pharmaradar360.com/article/council-backs-major-overhaul-of-eu-pharmaceutical-rules-4b7d1348205d7f9aPharmaRadar360en2026-09-28T13:37:57.000ZCouncil Backs Major Overhaul of EU Pharmaceutical Ruleshttps://www.pharmaradar360.com/article/core-advanced-credentialing-lessons-from-a-hospital-pilot-programme-7779229f5d264d7dPharmaRadar360en2026-09-28T13:36:57.000ZCore advanced credentialing: lessons from a hospital pilot programmehttps://www.pharmaradar360.com/article/mirum-posts-phase-3-hepatitis-win-for-commercially-differentiated-challenger-to-6406fec6953b3111PharmaRadar360en2026-09-28T13:36:17.000ZMirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Virhttps://www.pharmaradar360.com/article/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo-033-ras-mut-5648e5ead6976736PharmaRadar360en2026-09-28T13:34:59.000ZOncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Studyhttps://www.pharmaradar360.com/article/fda-hearing-on-psychedelics-concerns-but-overwhelmingly-positive-251f07e4cb827b18PharmaRadar360en2026-09-28T13:31:03.000ZFDA Hearing on Psychedelics: Concerns, But Overwhelmingly Positivehttps://www.pharmaradar360.com/article/abbvie-wins-fda-nod-for-parkinson-s-disease-drug-20086af8eafc60f9PharmaRadar360en2026-09-28T13:31:01.000ZAbbVie wins FDA nod for Parkinson’s disease drughttps://www.pharmaradar360.com/article/biotech-company-more-than-triples-new-haven-hq-space-bb59ed30932c450ePharmaRadar360en2026-09-28T13:30:01.000ZBiotech company more than triples New Haven HQ spacehttps://www.pharmaradar360.com/article/scynexis-bags-214m-barda-contract-for-antifungal-development-51009f0179a8ef7dPharmaRadar360en2026-09-28T13:29:32.000ZScynexis bags $214M BARDA contract for antifungal developmenthttps://www.pharmaradar360.com/article/biotech-act-europe-is-holding-back-its-food-biotech-leaders-887cf9976dd26ce8PharmaRadar360en2026-09-28T13:27:06.000ZBiotech Act: Europe is holding back its food biotech leadershttps://www.pharmaradar360.com/article/u-s-fda-approves-abbvie-s-juvmo-for-parkinson-s-disease-8e32bc4dacb923c8PharmaRadar360en2026-09-28T13:26:03.000ZU.S. FDA Approves AbbVie's JUVMO for Parkinson's Diseasehttps://www.pharmaradar360.com/article/viking-therapeutics-vktx-vk2735-data-look-strong-but-cash-burn-still-matters-5c4dab01dcd150cePharmaRadar360en2026-09-28T13:19:11.000ZViking Therapeutics (VKTX): VK2735 Data Look Strong, but Cash Burn Still Mattershttps://www.pharmaradar360.com/article/q-a-will-national-licensure-simplify-distributor-compliance-8b7c960ee55c6136PharmaRadar360en2026-09-28T13:18:40.000ZQ&A: Will National Licensure Simplify Distributor Compliance?https://www.pharmaradar360.com/article/independent-review-into-maternity-and-neonatal-services-at-leeds-teaching-hospit-ed0c3079210d1dfaPharmaRadar360en2026-09-28T13:17:05.000ZIndependent review into maternity and neonatal services at Leeds Teaching Hospitals NHS Trust: terms of referencehttps://www.pharmaradar360.com/article/atebrioz-becomes-third-fda-approved-drug-for-rare-fop-offering-a-daily-pill-for-bc3d9a47479f21c2PharmaRadar360en2026-09-28T13:15:38.000ZAtebrioz Becomes Third FDA-Approved Drug for Rare FOP, Offering a Daily Pill for Patients 12 and Olderhttps://www.pharmaradar360.com/article/european-pharmaceutical-review-issue-2-2026-b8f3c4499892e70ePharmaRadar360en2026-09-28T13:12:55.000ZEuropean Pharmaceutical Review Issue 2 2026https://www.pharmaradar360.com/article/tolerance-bio-licenses-tanabe-s-anti-il-33-thymus-antibody-120d1e290bd2208aPharmaRadar360en2026-09-28T13:12:10.000ZTolerance Bio Licenses Tanabe's Anti-IL-33 Thymus Antibodyhttps://www.pharmaradar360.com/article/the-hidden-cost-of-drug-law-federalism-how-state-drug-reforms-could-mislead-cons-fb277680dbe64693PharmaRadar360en2026-09-28T13:09:59.000ZThe Hidden Cost of Drug Law Federalism: How State Drug Reforms Could Mislead Consumershttps://www.pharmaradar360.com/article/dme-drug-remigromig-hits-primary-end-point-in-phase-3-trial-2b3bfc514ea92b41PharmaRadar360en2026-09-28T13:09:34.000ZDME Drug Remigromig Hits Primary End Point in Phase 3 Trialhttps://www.pharmaradar360.com/article/l-b-bohle-to-exhibit-qbcon-1-at-cphi-milan-2026-0d45cf4d62522d1fPharmaRadar360en2026-09-28T13:01:23.000ZL.B. Bohle to exhibit QbCon 1 at CPHI Milan 2026https://www.pharmaradar360.com/article/nonclinical-testing-rulemaking-update-fda-encourages-adoption-of-nams-over-anima-0edb8a5a9c4bd9d3PharmaRadar360en2026-09-28T13:00:56.000ZNonclinical Testing Rulemaking Update: FDA Encourages Adoption of NAMs Over Animal Testshttps://www.pharmaradar360.com/article/lilly-s-olumiant-gains-us-approval-for-adolescents-with-severe-alopecia-276f1ed243a2333ePharmaRadar360en2026-09-28T12:52:09.000ZLilly’s Olumiant gains US approval for adolescents with severe alopeciahttps://www.pharmaradar360.com/article/swiss-groups-seek-reforms-as-clinical-trial-numbers-fall-cec8ebe5f8687055PharmaRadar360en2026-09-28T12:52:07.000ZSwiss groups seek reforms as clinical trial numbers fallhttps://www.pharmaradar360.com/article/merck-and-daiichi-withdraw-us-filing-for-lung-cancer-adc-0b22f39971e507c2PharmaRadar360en2026-09-28T12:52:05.000ZMerck and Daiichi withdraw US filing for lung cancer ADChttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-22878ba5448174fdPharmaRadar360en2026-09-28T12:48:57.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/astellas-launches-phase-3-trial-of-kras-g12d-targeted-drug-in-advanced-lung-canc-8929bcbb11641b13PharmaRadar360en2026-09-28T12:45:05.000ZAstellas launches Phase 3 trial of KRAS G12D-targeted drug in advanced lung cancerhttps://www.pharmaradar360.com/article/hlb-s-fda-approved-acquired-bile-duct-drug-f6c68694d93cb7e4PharmaRadar360en2026-09-28T12:42:51.000ZHLB's FDA-Approved Acquired Bile Duct Drughttps://www.pharmaradar360.com/article/4d-molecular-starts-phase-3-trial-for-diabetic-eye-disease-drug-2ef4db146444b3a9PharmaRadar360en2026-09-28T12:37:59.000Z4D Molecular starts Phase 3 trial for diabetic eye disease drughttps://www.pharmaradar360.com/article/kodiak-s-stock-doubles-as-resurrected-eye-disease-drug-matches-eylea-in-phase-3-d6a5f93ce6bf26ebPharmaRadar360en2026-09-28T12:37:34.000ZKodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3https://www.pharmaradar360.com/article/tukaram-mundhe-on-sanjay-raut-s-extortion-charges-show-me-8bccee53c5869252PharmaRadar360en2026-09-28T12:37:08.000ZTukaram Mundhe on Sanjay Raut’s extortion charges: ‘Show me’https://www.pharmaradar360.com/article/abbvie-lands-fda-approval-for-next-generation-parkinson-s-drug-juvmo-39527c2cb61bb6cdPharmaRadar360en2026-09-28T12:17:09.000ZAbbVie lands FDA approval for next-generation Parkinson’s drug, Juvmohttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-legend-biotech-stock-rating-on-durability-data-f286c6567812a7efPharmaRadar360en2026-09-28T12:15:28.000ZH.C. Wainwright reiterates Legend Biotech stock rating on durability datahttps://www.pharmaradar360.com/article/eutecma-acquires-tempaid-creating-a-cold-chain-packaging-business-that-spans-pal-ac33bf7eb02a830bPharmaRadar360en2026-09-28T12:01:02.000Zeutecma Acquires Tempaid, Creating a Cold Chain Packaging Business That Spans Pallet to Parcel Across Europe, North America and Asiahttps://www.pharmaradar360.com/article/pms-fampridine-10-mg-tablet-affected-lot-may-contain-foreign-material-particles-cb5d498c627bb63aPharmaRadar360en2026-09-28T12:00:00.000ZPMS-FAMPRIDINE 10 mg Tablet: Affected lot may contain foreign material particles.https://www.pharmaradar360.com/article/omniasecuretm-mri-surescantm-2d8833077cd38fa9PharmaRadar360en2026-09-28T12:00:00.000ZOmniaSecure™ MRI SureScan™